PDF(Pubmed)
Abstract：
UNASSIGNED: Erectile dysfunction (ED) is a common disease among elderly men, and novel therapy methods are needed for drug-refractory ED. As an extracellular vesicle, stem cell-derived exosomes displayed erectile function improvement in rat ED models in some preclinical studies. However, the therapeutic efficacy has not been comprehensively evaluated.
UNASSIGNED: To study the therapeutic effects of stem cell-derived exosomes on ED in preclinical studies and to investigate the potential mechanisms responsible for the efficacy.
UNASSIGNED: The systematic literature search was conducted in Web of Science, PubMed, and Embase to retrieve studies utilizing stem cell-derived exosomes for ED treatment. We extracted data of intracavernous pressure/mean artery pressure (ICP/MAP), and cavernosum structural changes in rat ED models before and after stem cell-derived exosome therapy. RevMan 5.3 was used to perform meta-analyses of ICP/MAP and cavernosum microstructural changes. Publication bias was assessed with the Egger test and funnel plot by Stata 15.0 (StataCorp).
UNASSIGNED: Outcomes included ICP/MAP, smooth muscle, and endothelial markers-such as the ratio of smooth muscle to collagen and the expression of α-SMA (alpha smooth muscle actin), CD31 (cluster of differentiation 31), nNOS and eNOS (neuronal and endothelial nitric oxide synthase), TGF-β1 (transforming growth factor β1), and caspase 3 protein-to evaluate erectile function and microstructural changes. Forest plots of effect sizes were performed.
UNASSIGNED: Of 146 studies retrieved, 11 studies were eligible. Pooled analysis showed that stem cell-derived exosomes ameliorated damaged ICP/MAP (standardized mean difference, 3.68; 95% CI, 2.64-4.72; P < .001) and structural changes, including the ratio of smooth muscle to collagen and the expression of α-SMA, CD31, nNOS, eNOS, TGF-β1, and caspase 3 protein. Subgroup analysis indicated that exosome type and ED model type made no difference to curative effects.
UNASSIGNED: This meta-analysis suggests the therapeutic efficacy of stem cell-derived exosomes for ED. Exosomes may restore erectile function by optimizing cavernosum microstructures.
UNASSIGNED: To study the therapeutic effects of stem cell-derived exosomes on ED in preclinical studies and to investigate the potential mechanisms responsible for the efficacy.
UNASSIGNED: The systematic literature search was conducted in Web of Science, PubMed, and Embase to retrieve studies utilizing stem cell-derived exosomes for ED treatment. We extracted data of intracavernous pressure/mean artery pressure (ICP/MAP), and cavernosum structural changes in rat ED models before and after stem cell-derived exosome therapy. RevMan 5.3 was used to perform meta-analyses of ICP/MAP and cavernosum microstructural changes. Publication bias was assessed with the Egger test and funnel plot by Stata 15.0 (StataCorp).
UNASSIGNED: Outcomes included ICP/MAP, smooth muscle, and endothelial markers-such as the ratio of smooth muscle to collagen and the expression of α-SMA (alpha smooth muscle actin), CD31 (cluster of differentiation 31), nNOS and eNOS (neuronal and endothelial nitric oxide synthase), TGF-β1 (transforming growth factor β1), and caspase 3 protein-to evaluate erectile function and microstructural changes. Forest plots of effect sizes were performed.
UNASSIGNED: Of 146 studies retrieved, 11 studies were eligible. Pooled analysis showed that stem cell-derived exosomes ameliorated damaged ICP/MAP (standardized mean difference, 3.68; 95% CI, 2.64-4.72; P < .001) and structural changes, including the ratio of smooth muscle to collagen and the expression of α-SMA, CD31, nNOS, eNOS, TGF-β1, and caspase 3 protein. Subgroup analysis indicated that exosome type and ED model type made no difference to curative effects.
UNASSIGNED: This meta-analysis suggests the therapeutic efficacy of stem cell-derived exosomes for ED. Exosomes may restore erectile function by optimizing cavernosum microstructures.
摘要：
未经证实：勃起功能障碍（ED）是老年男性的常见疾病，药物难治性ED需要新的治疗方法。作为细胞外囊泡，在一些临床前研究中,干细胞来源的外泌体在大鼠ED模型中显示出勃起功能改善.然而,治疗效果尚未得到全面评估。
UNASSIGNED：在临床前研究中研究干细胞来源的外泌体对ED的治疗作用，并研究其疗效的潜在机制。
未经评估：在WebofScience中进行了系统的文献检索，PubMed,和Embase检索利用干细胞来源的外泌体治疗ED的研究。我们提取了海绵体内压/平均动脉压(ICP/MAP)数据，干细胞来源外泌体治疗前后大鼠ED模型的海绵体结构变化。RevMan5.3用于进行ICP/MAP和海绵体微结构变化的荟萃分析。Stata15.0（StataCorp）用Egger检验和漏斗图评估发表偏倚。
未经评估：结果包括ICP/MAP，平滑肌,和内皮标记-如平滑肌与胶原蛋白的比例和α-SMA（α平滑肌肌动蛋白）的表达，CD31（分化簇31），nNOS和eNOS（神经元和内皮型一氧化氮合酶），TGF-β1（转化生长因子β1），和caspase3蛋白-评估勃起功能和微观结构的变化。进行了效果大小的森林地块。
未经评估：在检索到的146项研究中，11项研究合格。汇集分析表明，干细胞来源的外泌体改善了受损的ICP/MAP(标准化平均差，3.68；95%CI，2.64-4.72；P<.001)和结构变化，包括平滑肌与胶原蛋白的比例和α-SMA的表达，CD31,nNOS,eNOS,TGF-β1和caspase3蛋白。亚组分析表明，外泌体类型和ED模型类型对疗效无影响。
未经批准：这项荟萃分析提示干细胞来源的外泌体对ED的治疗效果。外泌体可以通过优化海绵体微结构来恢复勃起功能。
UNASSIGNED：在临床前研究中研究干细胞来源的外泌体对ED的治疗作用，并研究其疗效的潜在机制。
未经评估：在WebofScience中进行了系统的文献检索，PubMed,和Embase检索利用干细胞来源的外泌体治疗ED的研究。我们提取了海绵体内压/平均动脉压(ICP/MAP)数据，干细胞来源外泌体治疗前后大鼠ED模型的海绵体结构变化。RevMan5.3用于进行ICP/MAP和海绵体微结构变化的荟萃分析。Stata15.0（StataCorp）用Egger检验和漏斗图评估发表偏倚。
未经评估：结果包括ICP/MAP，平滑肌,和内皮标记-如平滑肌与胶原蛋白的比例和α-SMA（α平滑肌肌动蛋白）的表达，CD31（分化簇31），nNOS和eNOS（神经元和内皮型一氧化氮合酶），TGF-β1（转化生长因子β1），和caspase3蛋白-评估勃起功能和微观结构的变化。进行了效果大小的森林地块。
未经评估：在检索到的146项研究中，11项研究合格。汇集分析表明，干细胞来源的外泌体改善了受损的ICP/MAP(标准化平均差，3.68；95%CI，2.64-4.72；P<.001)和结构变化，包括平滑肌与胶原蛋白的比例和α-SMA的表达，CD31,nNOS,eNOS,TGF-β1和caspase3蛋白。亚组分析表明，外泌体类型和ED模型类型对疗效无影响。
未经批准：这项荟萃分析提示干细胞来源的外泌体对ED的治疗效果。外泌体可以通过优化海绵体微结构来恢复勃起功能。
